

# Jason A Tye-Din

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1287122/publications.pdf>

Version: 2024-02-01

75  
papers

3,488  
citations

147801

31  
h-index

144013

57  
g-index

76  
all docs

76  
docs citations

76  
times ranked

3459  
citing authors

#	ARTICLE	IF	CITATIONS
1	Iron deficiency. <i>Lancet, The</i> , 2021, 397, 233-248.	13.7	396
2	Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease. <i>Science Translational Medicine</i> , 2010, 2, 41ra51.	12.4	393
3	Duodenal Bacteria From Patients With Celiac Disease and Healthy Subjects Distinctly Affect Gluten Breakdown and Immunogenicity. <i>Gastroenterology</i> , 2016, 151, 670-683.	1.3	177
4	A Structural and Immunological Basis for the Role of Human Leukocyte Antigen DQ8 in Celiac Disease. <i>Immunity</i> , 2007, 27, 23-34.	14.3	157
5	Genome mapping of seed-borne allergens and immunoresponsive proteins in wheat. <i>Science Advances</i> , 2018, 4, eaar8602.	10.3	130
6	The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. <i>Clinical Immunology</i> , 2010, 134, 289-295.	3.2	125
7	Update 2020: nomenclature and listing of celiac disease-relevant gluten epitopes recognized by CD4+ T cells. <i>Immunogenetics</i> , 2020, 72, 85-88.	2.4	125
8	Biased T Cell Receptor Usage Directed against Human Leukocyte Antigen DQ8-Restricted Gliadin Peptides Is Associated with Celiac Disease. <i>Immunity</i> , 2012, 37, 611-621.	14.3	121
9	Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 479-493.	8.1	113
10	Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies. <i>Frontiers in Pediatrics</i> , 2018, 6, 350.	1.9	111
11	T cells in peripheral blood after gluten challenge in coeliac disease. <i>Gut</i> , 2005, 54, 1217-1223.	12.1	110
12	Accurate and Robust Genomic Prediction of Celiac Disease Using Statistical Learning. <i>PLoS Genetics</i> , 2014, 10, e1004137.	3.5	95
13	T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 49-61.	8.2	91
14	A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways. <i>BMC Medicine</i> , 2013, 11, 188.	5.5	88
15	Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. <i>Science Advances</i> , 2019, 5, eaaw7756.	10.3	84
16	The mosaic oat genome gives insights into a uniquely healthy cereal crop. <i>Nature</i> , 2022, 606, 113-119.	27.8	70
17	Circulating gluten-specific FOXP3 + CD39 + regulatory T cells have impaired suppressive function in patients with celiac disease. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1592-1603.e8.	2.9	63
18	Current and emerging therapies for coeliac disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 181-195.	17.8	63

#	ARTICLE	IF	CITATIONS
19	Ingestion of oats and barley in patients with celiac disease mobilizes cross-reactive T cells activated by avenin peptides and immuno-dominant hordein peptides. <i>Journal of Autoimmunity</i> , 2015, 56, 56-65.	6.5	62
20	Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease. <i>Gut</i> , 2006, 55, 485-491.	12.1	56
21	Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 901-910.	3.7	51
22	Ex-vivo whole blood secretion of interferon (IFN)- $\gamma$ and IFN- $\gamma$ -inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN- $\gamma$ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2.5-associated coeliac disease. <i>Clinical and Experimental Immunology</i> , 2014, 175, 305-315.	2.6	50
23	Food knowledge and psychological state predict adherence to a gluten-free diet in a survey of 5310 Australians and New Zealanders with coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 78-86.	3.7	50
24	Consistency in Polyclonal T-cell Responses to Gluten Between Children and Adults With Celiac Disease. <i>Gastroenterology</i> , 2015, 149, 1541-1552.e2.	1.3	46
25	Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness. <i>Psychology, Health and Medicine</i> , 2017, 22, 524-534.	2.4	43
26	Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an Australasian perspective. <i>Internal Medicine Journal</i> , 2015, 45, 441-450.	0.8	40
27	The Risk of Contracting COVID-19 Is Not Increased in Patients With Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 391-393.	4.4	38
28	Coeliac disease: a unique model for investigating broken tolerance in autoimmunity. <i>Clinical and Translational Immunology</i> , 2016, 5, e112.	3.8	37
29	Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. <i>Clinical and Experimental Immunology</i> , 2019, 199, 68-78.	2.6	36
30	Surveillance of FAP: a prospective blinded comparison of capsule endoscopy and other GI imaging to detect small bowel polyps. <i>Hereditary Cancer in Clinical Practice</i> , 2010, 8, 3.	1.5	34
31	Immunopathogenesis of celiac disease. <i>Current Gastroenterology Reports</i> , 2008, 10, 458-465.	2.5	33
32	Maintenance of a gluten free diet in coeliac disease: The roles of self-regulation, habit, psychological resources, motivation, support, and goal priority. <i>Appetite</i> , 2018, 125, 356-366.	3.7	32
33	A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 <sup>®</sup> in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet. <i>Gastroenterology</i> , 2011, 140, S-437-S-438.	1.3	31
34	Dissecting the T-cell response to hordeins in coeliac disease can develop barley with reduced immunotoxicity. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1184-1191.	3.7	28
35	Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 244-252.	3.7	27
36	Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity. <i>United European Gastroenterology Journal</i> , 2020, 8, 108-118.	3.8	26

#	ARTICLE	IF	CITATIONS
37	Genomic prediction of celiac disease targeting HLA-positive individuals. <i>Genome Medicine</i> , 2015, 7, 72.	8.2	25
38	Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. <i>BMC Medicine</i> , 2020, 18, 362.	5.5	22
39	A systematic approach for comprehensive T-cell epitope discovery using peptide libraries. <i>Bioinformatics</i> , 2005, 21, i29-i37.	4.1	17
40	Gluten in "gluten-free" food from food outlets in Melbourne: a cross-sectional study. <i>Medical Journal of Australia</i> , 2018, 209, 42-43.	1.7	17
41	Preparation and Characterization of Avenin-Enriched Oat Protein by Chill Precipitation for Feeding Trials in Celiac Disease. <i>Frontiers in Nutrition</i> , 2019, 6, 162.	3.7	15
42	Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease. <i>Clinical and Experimental Immunology</i> , 2021, 204, 321-334.	2.6	15
43	A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease. <i>Frontiers in Immunology</i> , 2021, 12, 661622.	4.8	14
44	For Celiac Disease, Diagnosis Is Not Enough. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 900-901.	4.4	11
45	Characterisation of clinical and immune reactivity to barley and rye ingestion in children with coeliac disease. <i>Gut</i> , 2020, 69, 830-840.	12.1	10
46	Systematic review: Exploration of the impact of psychosocial factors on quality of life in adults living with coeliac disease. <i>Journal of Psychosomatic Research</i> , 2021, 147, 110537.	2.6	10
47	Quality of life in coeliac disease: relationship between psychosocial processes and quality of life in a sample of 1697 adults living with coeliac disease. <i>Journal of Psychosomatic Research</i> , 2021, 151, 110652.	2.6	10
48	Hydroxychloroquine inhibits the mitochondrial antioxidant system in activated T cells. <i>IScience</i> , 2021, 24, 103509.	4.1	10
49	Aspiration in the Context of Upper Gastrointestinal Endoscopy. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 223-225.	1.7	9
50	T cells in coeliac disease: a rational target for diagnosis and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 583-584.	17.8	9
51	Gluten in "gluten-free" manufactured foods in Australia: a cross-sectional study. <i>Medical Journal of Australia</i> , 2018, 209, 448-449.	1.7	8
52	Risk perception and knowledge of COVID-19 in patients with celiac disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 1213-1225.	3.3	8
53	Circulating gluten-specific, but not CMV-specific, CD39 + regulatory T cells have an oligoclonal TCR repertoire. <i>Clinical and Translational Immunology</i> , 2020, 9, e1096.	3.8	7
54	Interpreting tests for coeliac disease: Tips, pitfalls and updates. , 2018, 47, 28-33.		7

#	ARTICLE	IF	CITATIONS
55	The practice and perception of precautionary allergen labelling by the Australasian food manufacturing industry. <i>Clinical and Experimental Allergy</i> , 2017, 47, 961-968.	2.9	5
56	Sa1396 A Single Intradermal (ID) Injection of Nexvax2 <sup>®</sup> , a Peptide Composition With Dominant Epitopes for Gluten-Reactive CD4+ T Cells, Activates T Cells and Triggers Acute Gastrointestinal Symptoms in HLA-DQ2.5+ People With Celiac Disease (CeD). <i>Gastroenterology</i> , 2016, 150, S304.	1.3	4
57	High rates of variation in HLA-DQ2/DQ8 testing for coeliac disease: results from an RCPAQAP pilot program. <i>Journal of Clinical Pathology</i> , 2018, 71, 900-905.	2.0	4
58	Rapid, Loop-Mediated Isothermal Amplification Detection of Celiac Disease Risk Alleles. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 307-315.	2.8	3
59	Longitudinal assessment of the common sense model before and during the COVID-19 pandemic: A large coeliac disease cohort study. <i>Journal of Psychosomatic Research</i> , 2022, 153, 110711.	2.6	3
60	846 Efficacy, Safety, Tolerability, and Immunological Effects of Nexvax2 <sup>®</sup> , a Peptide-Based Therapeutic Vaccine, Administered by Intra-Dermal (ID) Injection Twice-Weekly for 8-Weeks in HLA-DQ2.5+ Celiac Disease (CeD). <i>Gastroenterology</i> , 2016, 150, S180.	1.3	2
61	Sa1395 Nexvax2 <sup>®</sup> , a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD). <i>Gastroenterology</i> , 2016, 150, S304.	1.3	2
62	Point-of-care testing for coeliac disease antibodies – what is the evidence?. <i>Medical Journal of Australia</i> , 2015, 202, 418-419.	1.7	2
63	Review article: Follow-up of coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, .	3.7	2
64	Editorial: a novel approach to monitor mucosal healing in coeliac disease – as simple as shifting goalposts?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 894-895.	3.7	1
65	Serum IL-2 and IL-8 are Elevated within 4 h after Gluten Ingestion in Celiac Disease (CED) Patients on Gluten-Free Diet (GFD) and Potential to Resolve Indeterminate Diagnoses for Patients on GFD. <i>Gastroenterology</i> , 2017, 152, S114.	1.3	1
66	Discrepancies in genetic testing results for coeliac disease: call for standardised testing and reporting. <i>Medical Journal of Australia</i> , 2017, 207, 179-180.	1.7	1
67	Resolving incomplete single nucleotide polymorphism tagging of HLA-DQ2.2 for coeliac disease genotyping using digital droplet PCR. <i>Hla</i> , 2018, 91, 280-288.	0.6	1
68	Editorial: inaccuracies in attribution of symptoms due to gluten – not just in those with self-reported noncoeliac gluten sensitivity. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 403-404.	3.7	1
69	354 Dominance, Hierarchy and Redundancy of T Cell Stimulatory Peptides in Celiac Disease. <i>Gastroenterology</i> , 2009, 136, A-57.	1.3	0
70	A Population Study to Optimize the Role of Serology and Genetics in the Diagnosis of Celiac Disease (CD). <i>Gastroenterology</i> , 2011, 140, S-440.	1.3	0
71	Sa1317 A Whole Blood Cytokine Release Assay Employing Short-Term Gluten Challenge Identifies Patients With Celiac Disease on a Gluten Free Diet. <i>Gastroenterology</i> , 2012, 142, S-271.	1.3	0
72	Sa1398 Immunogenic Gluten Is Modulated by Small Intestinal Bacterial Hydrolysis. <i>Gastroenterology</i> , 2016, 150, S304.	1.3	0

#	ARTICLE	IF	CITATIONS
73	Reply. Gastroenterology, 2016, 150, 779-780.	1.3	0
74	824 “ Acute Gluten-Induced Symptoms in Celiac Disease (CED) are Quantitatively Correlated with Serum Cytokine Response. Gastroenterology, 2019, 156, S-177.	1.3	0
75	Editorial: lack of gastrointestinal symptoms caused by gluten in patients without coeliac disease”time to ditch the “gluten”™ from “non”coeliac gluten sensitivity”™. Alimentary Pharmacology and Therapeutics, 2022, 56, 340-341.		0